CSL Stock

CSL Revenue

Delisted·Jun 19, 2026

The The revenue of CSL (CSL.AX) as of Jul 23, 2026 is 15.56 B USD. In the previous year, The revenue was 14.80 B USD — a change of 5.12% (higher).

Revenue

15.56 BUSD

YoY

5.12%

Last updated:

In 2026, CSL's sales reached 15.56 B USD, a 5.12% difference from the 14.80 B USD sales recorded in the previous year.

Revenue has compounded at 10.9% per year over the past 19 years to 15.56 B USD.

The CSL Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

REVENUE (B USD)
GROSS MARGIN (%)
Date
REVENUE (B USD)
GROSS MARGIN (%)
Jan 1, 2024
14.80 base
51.83 base
Jan 1, 2025
15.56 base
51.93 base
Jan 1, 2026 (e)
16.00 base
50.48 base
Jan 1, 2027 (e)
16.66 base
48.48 base
Jan 1, 2028 (e)
17.46 base
46.28 base
Jan 1, 2029 (e)
19.12 base
42.25 base
Jan 1, 2030 (e)
20.85 base
38.74 base
Jan 1, 2031 (e)
22.03 base
36.68 base
YEARREVENUE (B USD)GROSS MARGIN (%)
2031 est 22.0336.68
2030 est 20.8538.74
2029 est 19.1242.25
2028 est 17.4646.28
2027 est 16.6648.48
2026 est 16.0050.48
2025 15.5651.93
2024 14.8051.83
2023 13.3151.28
2022 10.5654.27
2021 10.3156.68
2020 9.1557.11
2019 8.5455.95
2018 7.9255.38
2017 6.9251.94
2016 6.1250.08
2015 5.6353.70
2014 5.5252.86
2013 5.1353.38
2012 4.7750.39
2011 4.2650.74
2010 4.0652.59
2009 3.6952.21
2008 3.4049.17
2007 2.6047.56
2006 2.1741.39
Access this data via the Eulerpool API

CSL Revenue

CSL Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
14.80 B USD
3.81 B USD
2.64 B USD
Jan 1, 2025
15.56 B USD
4.10 B USD
3.00 B USD
Jan 1, 2026 (e)
16.00 B USD
4.86 B USD
3.40 B USD
Jan 1, 2027 (e)
16.66 B USD
5.12 B USD
3.67 B USD
Jan 1, 2028 (e)
17.46 B USD
5.44 B USD
3.96 B USD
Jan 1, 2029 (e)
19.12 B USD
5.70 B USD
4.41 B USD
Jan 1, 2030 (e)
20.85 B USD
5.94 B USD
4.75 B USD
Jan 1, 2031 (e)
22.03 B USD
0.00 USD
5.07 B USD

CSL Margins

CSL stock margins

The CSL margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CSL. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CSL.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
51.83 %
25.76 %
17.85 %
Jan 1, 2025
51.93 %
26.38 %
19.30 %
Jan 1, 2026 (e)
51.93 %
30.39 %
21.27 %
Jan 1, 2027 (e)
51.93 %
30.71 %
22.05 %
Jan 1, 2028 (e)
51.93 %
31.16 %
22.69 %
Jan 1, 2029 (e)
51.93 %
29.82 %
23.09 %
Jan 1, 2030 (e)
51.93 %
28.50 %
22.80 %
Jan 1, 2031 (e)
51.93 %
0.00 %
23.01 %

CSL Stock analysis

What does CSL do? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL is one of the most popular companies on Eulerpool.

Revenue Details

Understanding CSL's Sales Figures

The sales figures of CSL originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing CSL’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize CSL's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in CSL’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about CSL stock

The revenue of CSL is 15.56 B USD in 2026.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — CSL

All Key Metrics — CSL